Effective immediately, Evonik Industries is increasing the prices for the products L-Ornithine-L-Aspartate, L-Proline, L-Lysine salts, LMethionine, L-Arginine-L-Aspartate, Glycine and all other cGMP-grade amino acids. The increase amounts to 10 – 20 percents and applies globally to all new orders and new supply agreements.
Evonik Rexim with its production sites in Ham (France) and Nanning (China) is a major supplier of amino acids and amino acid derivatives in highly purified pharmaceutical quality (cGMP grade) and nutraceutical quality. These products are used in the Health Care industry for parenteral and enteral nutrition as well as in cell culture media and for production of pharmaceutical active ingredients.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2011 more than 33,000 employees generated sales of around €14.5 billion and an operating profit (EBITDA) of about €2.8 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.